[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The Skin Center Dermatology Group\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":60},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100576917","phase-4-tirbanibulin-for-pediatric-warts-100576917",false,"NCT06791525","Tirbanibulin for Pediatric Warts","Single-arm, Open-label Study of Tirbanibulin 1% Ointment to Treat Warts on the Hands in Pediatric Patients","Inclusion Criteria:\n\n1. Age 8-18\n2. Subject and their legally authorized representative must be able to understand and be willing to adhere to all protocol requirements and voluntarily sign and date informed consent and assent for minors.\n3. Subject is judged to be in good health as determined by the Principal Investigator, based upon the results of the screening assessments and medical history.\n4. Diagnosis of warts on the hands\n5. Wart count on the hands and 3-10\n\nExclusion Criteria:\n\n1. Wart duration \\>2 years.\n2. More than 10 warts in non-hand areas.\n3. Total wart surface area on the hands bigger than 100 cm2\n4. Prior treatment failure with the following modalities:\n\n1\\. intralesional immunotherapy 2. intralesional bleomycin, 5-fluorouracil, methotrexate 3. intralesional cidofovir 5. Any over the counter, prescription topical, or in-office procedural wart treatment within 6 weeks of baseline (Day 1) 6. Known immuno-suppressed state due to disease or medication, medical treatment o 7. Known allergy to any component of the IP 8. Any conditions that, in the Principal Investigator's opinion, may interfere with the course of the study","ALL","8 Years","18 Years",{"count":20,"type":21},10,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Warts are common, benign skin lesions caused by the human papillomavirus (HPV). Treatment is challenging, particularly in the pediatric population, where standard modalities such as cryotherapy and intralesional immunotherapy are poorly tolerated. Existing topical treatments, such as imiquimod and 5-fluorouracil, have low efficacy and require prolonged use. Case reports suggest tirbanibulin ointment may provide an effective and well-tolerated alternative for pediatric warts. This study will evaluate the efficacy and safety of tirbanibulin ointment in treating pediatric hand warts.",[27],"Warts Hand","RECRUITING","2026-04-21",{"date":31,"type":32},"2026-04-23","ACTUAL",{"date":34,"type":32},"2025-05-01",{"date":36,"type":21},"2026-12-30",{"name":38,"class":39},"The Skin Center Dermatology Group","INDUSTRY",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":22,"phases":48,"briefSummary":49,"conditions":50,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":40},"100623402","phase-4-nemolizumab-to-treat-lichen-planopilaris-a-noncontrolled-prospective-pilot-study-100623402","NCT07396168","Nemolizumab to Treat Lichen Planopilaris, a Noncontrolled, Prospective, Pilot Study.","Inclusion Criteria:\n\n* Age ≥18 years.\n* Clinical and\u002For histopathologic diagnosis of LPP.\n* Presence of scalp pruritus.\n* Average Peak Pruritus Numerical Rating Scale (PP-NRS) score ≥4 in the 7 days prior to Day 1.\n* Ability and willingness to provide written informed consent and comply with study procedures.\n* Willingness to undergo optional scalp biopsy for research purposes.\n\nExclusion Criteria:\n\n* Other forms of alopecia that may interfere with study assessments.\n* Any systemic disease associated with hair loss.\n* Inflammatory or infectious scalp disease that may interfere with the study.\n* Any other conditions associated with pruritus.\n* Prior use of nemolizumab.\n* Current treatment with systemic or topical JAK inhibitors or biologics (unless appropriate washout period completed; minimum 12 weeks).\n* Current treatment with DMARDs (unless appropriate washout period completed; minimum 12 weeks).\n* Prior treatment failure of scarring alopecia with systemic or topical JAK inhibitors or\n* biologics.\n* Current treatment with topical or intralesional corticosteroids (unless appropriate washout period completed; minimum 4 weeks).\n* Any other current treatments for hair loss (e.g., oral\u002Ftopical minoxidil, PRP) unless stable for at least 6 months or 3 months washout completed.\n* Allergy or hypersensitivity to nemolizumab or any excipients.\n* Pregnancy or unwillingness to use highly effective contraception.\n* Any medical condition that, in the opinion of the investigator, may interfere with study participation or interpretation of results.",{"count":20,"type":21},[24],"Lichen planopilaris (LPP) is a primary lymphocytic cicatricial alopecia characterized by progressive, permanent hair loss and scalp symptoms such as pruritus and burning. Current treatments-including topical and intralesional corticosteroids, hydroxychloroquine, and immunosuppressants-are often inadequate, with limited evidence for efficacy and frequent treatment switching or discontinuation due to side effects or lack of response.1,2 Recent systematic reviews and meta-analyses highlight the need for new, targeted therapies. 3,4 Nemolizumab, an IL-31 receptor antagonist, FDA-approved for prurigo nodularis and atopic dermatitis, has demonstrated efficacy in pruritic and fibrosing dermatoses, making it a rational candidate for LPP.",[51],"Lichen Plano-Pilaris","2026-02-07",{"date":54,"type":32},"2026-02-10",{"date":56,"type":32},"2026-02-01",{"date":58,"type":21},"2027-06",{"name":38,"class":39},""]